Novo Nordisk A/S (CPH:NOVO.B)
Denmark · Delayed Price · Currency is DKK 306.15
+1.05 (0.34%)
Aug 10, 2026, 4:59 PM CET
Novo Nordisk Financials Overview
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 329,431 | 309,064 | 290,403 | 232,261 | 176,954 | 140,800 |
Revenue Growth | 5.61% | 6.43% | 25.03% | 31.25% | 25.68% | 10.91% |
Gross Profit Gross Profit Growth | 270,092 | 254,687 | 246,843 | 196,942 | 148,530 | 117,142 |
Operating Income Operating Income Growth | 161,385 | 140,618 | 138,901 | 104,698 | 75,618 | 59,217 |
Net Income Net Income Growth | 116,443 | 102,434 | 100,988 | 83,683 | 55,525 | 47,757 |
Earnings Per Share EPS Growth | 26.20 | 23.03 | 22.63 | 18.62 | 12.22 | 10.37 |
EPS Growth | 4.98% | 1.77% | 21.54% | 52.37% | 17.84% | 15.16% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Rybelsus Rybelsus Growth | 20,545 | 22,093 | 23,301 | 18,750 | 11,299 | 4,838 |
Ozempic Ozempic Growth | 121,769 | 127,089 | 120,342 | 95,718 | 59,750 | 33,705 |
Victoza Victoza Growth | 1,463 | 3,020 | 5,482 | 8,664 | 12,322 | 15,054 |
Long-Acting Insulin Long-Acting Insulin Growth | 17,544 | 18,755 | 19,095 | 14,905 | 16,741 | 18,064 |
Premix Insulin Premix Insulin Growth | 10,051 | 10,315 | 10,789 | 9,574 | 10,562 | 11,203 |
Fast-Acting Insulin Fast-Acting Insulin Growth | 17,635 | 18,583 | 18,522 | 15,949 | 17,463 | 17,687 |
Human Insulin Human Insulin Growth | 4,750 | 5,484 | 6,967 | 7,594 | 8,186 | 9,052 |
Other Diabetes Care Other Diabetes Care Growth | 2,107 | 1,770 | 2,120 | 2,312 | 3,225 | 3,594 |
Wegovy Wegovy Growth | 85,411 | 79,106 | 58,206 | 31,343 | 6,188 | 1,386 |
Saxenda Saxenda Growth | 2,204 | 3,241 | 6,940 | 10,289 | 10,676 | 7,014 |
Rare Blood Disorders Rare Blood Disorders Growth | 11,467 | 11,955 | 12,138 | 11,776 | 11,706 | 10,217 |
Rare Endocrine Disorders Rare Endocrine Disorders Growth | 5,912 | 5,959 | 4,993 | 3,836 | 7,138 | 7,303 |
Other Rare Disease Other Rare Disease Growth | 1,813 | 1,694 | 1,508 | 1,551 | 1,698 | 1,683 |
Revenue (Total) Revenue (Total) Growth | 329,431 | 309,064 | 290,403 | 232,261 | 176,954 | 140,800 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 44,982 | 26,962 | 26,308 | 30,230 | 23,574 | 17,485 |
Total Debt Total Debt Growth | 140,127 | 130,958 | 102,787 | 27,006 | 25,784 | 26,645 |
Net Cash (Debt) Net Cash Growth | -95,145 | -103,996 | -76,479 | 3,224 | -2,210 | -9,160 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -21.40 | -23.38 | -17.14 | 0.72 | -0.49 | -1.99 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 131,881 | 119,102 | 120,968 | 108,908 | 78,887 | 55,000 |
Capital Expenditures CapEx Growth | -56,043 | -60,140 | -47,164 | -25,806 | -12,146 | -6,335 |
Free Cash Flow Free Cash Flow Growth | 75,838 | 58,962 | 73,804 | 83,102 | 66,741 | 48,665 |
Free Cash Flow Growth | 14.30% | -20.11% | -11.19% | 24.51% | 37.14% | 5.50% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 81.99% | 82.41% | 85.00% | 84.79% | 83.94% | 83.20% |
Operating Margin | 48.99% | 45.50% | 47.83% | 45.08% | 42.73% | 42.06% |
Pretax Margin | 45.15% | 42.24% | 43.80% | 45.07% | 39.03% | 41.96% |
Profit Margin | 35.35% | 33.14% | 34.77% | 36.03% | 31.38% | 33.92% |
FCF Margin | 23.02% | 19.08% | 25.41% | 35.78% | 37.72% | 34.56% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 11.700 | 11.700 | 11.400 | 9.400 | 6.200 | 5.200 |
Dividend Per Share Growth | 2.63% | 2.63% | 21.28% | 51.61% | 19.23% | 14.29% |
Dividend Yield | 3.83% | 3.72% | 1.94% | 1.45% | 1.44% | 1.56% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 11.69 | 14.11 | 27.45 | 37.19 | 38.16 | 35.07 |
Forward PE | 15.47 | 13.73 | 23.68 | 32.62 | 40.03 | 34.03 |
P/FCF Ratio | 17.85 | 24.51 | 37.56 | 37.45 | 31.75 | 34.42 |
PS Ratio | 4.11 | 4.68 | 9.55 | 13.40 | 11.97 | 11.90 |